Alnylam Pharmaceuticals | ALNY - 应收帐款人

金融业

USD

USD 5.13B

现金及等价物

USD 1.71B

USD 211.12M

USD 4.22B

USD 1.35B

USD 1.28B

USD 137.59M

USD 145.22M

2.23K

EPS每股收益

USD 1.99

股本和储备

USD 1.08B

USD 825.01M

债务利息支出

USD 69.29M

USD 26.63M

USD 2.48B

USD 38.13B

USD 205.99M

USD 898.54M

USD 137.59M

普通股股本

USD 133.44M

80.04

USD 221.65M

USD 1.17B

销售和管理费用

USD 282.51M

USD 200.15M

贸易债权人

USD 126.63M

应收帐款人

USD 883.96M

	应收帐款人	更改		日
Acadia Pharmaceuticals	USD 148.38M		153K	2026-03
Agios Pharmaceuticals	USD 16.13M		5.56M	2026-03
Alnylam Pharmaceuticals	USD 883.96M		106.39M	2026-03
Amgen	USD 9.14B		432M	2026-03
Arrowhead Research	USD 15.68M		203.19M	2026-03
BioCryst Pharmaceuticals	USD 106.82M		15.49M	2025-12
BioMarin Pharmaceutical	USD 903.91M		4.3M	2026-03
Incyte	USD 1.05B		27.09M	2026-03
Ionis Pharmaceuticals	USD 74M		8M	2026-03
Moderna	USD 71M		113M	2026-03
Neurocrine Biosciences	USD 768.1M		81.3M	2026-03
Novartis	USD 12.29B		3.3B	2025-12
PTC Therapeutics	USD 181.62M		21.45M	2025-12
Regeneron Pharmaceuticals	USD 5.73B		10.1M	2026-03
Sangamo BioSciences	USD 581K		110K	2024-06
Sanofi	EUR 397M		186.13M	2025-12
Sarepta Therapeutics	USD 547.91M		149.68M	2026-03
Takeda	JPY 876.35B		118.43B	2026-03
Tectonic Therapeutic	USD 0		270K	2023-12
Ultragenyx Pharmaceutical	USD 60M		98M	2026-03
Vertex Pharmaceuticals	USD 2B		56.7M	2026-03
Xencor	USD 12M		17.3M	2026-03